| Exclusion Criteria: | 1) Patient plans to undergo autologous or allogeneic bone marrow transplantation within 4 weeks of the initiation of vorinostat administration.
2) Patient had prior treatment with an HDAC inhibitor (e.g., Depsipeptide, MS-275, LAQ-824, PXD-101, valproic acid, etc.)
3) Patient with concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of vorinostat.
4) Patient with clinically significant illness including, but not limited to the following: active systemic infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled cardiac arrhythmia, renal failure or any other condition (including laboratory abnormalities) that in the opinion of the Investigator places the patient at unacceptable risk for adverse outcome if he/she were to participate in the study.
5) Patient with psychiatric illness/social situations that would limit compliance with study medication and requirements.
6) Patient is pregnant or lactating.
7) Patient with known human immunodeficiency virus (HIV) infection.
8) Patient with active hepatitis B and/or hepatitis C infection.
9) Patient with a "currently active" second malignancy, other than non-melanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for more than 5 years and are considered by their physician to be at less than 30% risk of relapse.
10) Patient with non-secretory myeloma.
11) Patient with plasma cell leukemia defined as the presence of more than 20% plasma cells in the peripheral blood and an absolute plasma cell count of at least 2000 microL.
12) Patient with corrected serum calcium of greater than 11.5 mg/dL.
13) Patient with pre-existing neuropathy equal to or greater than Grade 2.
14) Patient with a history of allergic reaction attributable to compounds containing boron or mannitol. |